Researchers at Oregon State University have watched, in real time, how certain metals encourage the protein clumping associated with Alzheimer's disease. Working in a laboratory setting, the team used a molecule measuring technique to follow the process as it unfolded, rather than inferring it after the fact from static snapshots.
The work was led by Marilyn Rampersad Mackiewicz, an associate professor of chemistry in the OSU College of Science, with a team of undergraduate students. Along with observing metals promoting the clumping that leads to the blocked neural pathways seen in Alzheimer's, the researchers also watched molecules called chelators, which bind metals, disrupt and in some cases reverse that clumping.
That second observation is the part with the clearest practical edge. If chelators can pull apart clumps as well as prevent them from forming, watching exactly how they behave gives chemists concrete information for designing better drug candidates rather than screening compounds blindly.
Alzheimer's remains the most common form of dementia and, according to the Centers for Disease Control and Prevention, the sixth-leading cause of death among people 65 and older. This research sits at the early, laboratory end of that effort - a look at chemistry in a test system, not a treatment - but it addresses a question that has to be answered before metal-targeting drugs can be designed with any precision.